The human trials of the coronavirus vaccine COVAXIN, developed by Bharat Biotech, have begun at Rohtak’s Post-Graduate Institute of Medical Sciences on Friday, Haryana Health Minister Anil Vij tweeted. The Harayana state minister also said that there have been no adverse side effects reported on the subjects so far.
“Human trial with Corona vaccine (COVAXIN) of Bharat Biotech started at PGI Rohtak today. Three subjects were enrolled today. All have tolerated the vaccine very well. There were no adverse efforts,” Vij tweeted.
https://twitter.com/anilvijminister/status/1284040360453214208?ref_src=twsrc%5EtfwBharat Biotech’s COVAXIN to be launched on August 15
It is pertinent to note that this is the same coronavirus vaccine that the Indian Council of Medical Research (ICMR), the apex body for the medical research in the country, had announced earlier of being released for the public use by August 15.
Hyderabad-based Bharat Biotech successfully developed COVAXIN™ in collaboration with the ICMR and National Institute of Virology (NIV). The SARS-CoV-2 strain was isolated in NIV, Pune and transferred to Bharat Biotech for the effort.
The ICMR, in its letter to the stakeholders, claimed that COVAXIN™ is the first indigenous vaccine being developed by India and is one of the top priority projects which is being monitored at the topmost level of the Government. The vaccine is derived from a strain of SARS-CoV-2 isolated by ICMR-National Institute of virology. Pune- ICMR and BBIL are jointly working for the preclinical as well as clinical development of this vaccine, the letter read.